CALCIMEDICA ANNOUNCES THAT FDA HAS STRONGLY RECOMMENDED MOVING TO A BLINDED PLACEBO-CONTROLLED TRIAL WITH AUXORA™ IN PATIENTS WITH SEVERE COVID-19 PNEUMONIA